Work

Pause at Your Own Peril: A Case Series on Rebound Pulmonary Hypertension

Year: 2022

Type: article

Abstract: Severe pulmonary arterial hypertension (PAH) is associated with high morbidity and mortality. Therapeutic approaches for intermediate- and high-risk pulmonary arterial hypertension have now shifted toward initial combination management, often including parenteral epoprostenol and iloprost and early assessment for a lung transplant. After the initiation of therapy, usually various combinations of different classes of medication, it is important to consider the potential interruption in therapy causing rebound PAH. We present two patients recently admitted to our hospital with rebound symptoms after interruption of their pulmonary vasodilator therapy.

Source: Cureus

DOI: 10.7759/cureus.25552

Authors: Sindhubarathi Murali, Subrat Khanal, Sanchari Banerjee, Omari Christie, Kartik Ramakrishna

Institution: SUNY Upstate Medical University

Language: English

Topic: Pulmonary Hypertension Research and Treatments

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4282007653